Alvotech to present at upcoming investor conferences in September
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alvotech (NASDAQ: ALVO; ALVO-SDB) announced that Founder and Chairman Robert Wessman and Chief Strategy Officer Dr. Balaji V. Prasad will take part in two New York investor events in September 2026: a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15 at 12:20 pm ET (16:20 GMT), and investor meetings at Deutsche Bank's 2026 Healthcare Summit on September 17.
A live webcast of the Morgan Stanley fireside chat will be available via the Investors section of Alvotech's website, with a replay accessible for 90 days.
Details
News Market Reaction – ALVO
On Aug 27, the day this news came out, ALVO closed 0.61% below the previous close. Our momentum scanner recorded 2 alerts in the available session data.
Data tracked by StockTitan Argus for the Aug 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Founder and Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in September as follows:
- Morgan Stanley 24th Annual Global Healthcare Conference in New York – Fireside chat on Tuesday, September 15, 2026 at 12:20 pm ET (16:20 GMT)
- Deutsche Bank's 2026 Healthcare Summit in New York – Hosting investor meetings on Thursday, September 17, 2026.
A live webcast of the fireside chat will be available to the general public and can be accessed in the Investors Section of Alvotech's website under Events and Presentations. After the event, a recording will be available for replay for 90 days.
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com
Investors
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez
alvotech.ir@alvotech.com
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.